Kezar Life Sciences GAAP EPS of -$1.53 beats by $0.42 [Seeking Alpha]
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
Kezar Life Sciences (NASDAQ:KZR) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "strong sell" rating.
Kezar Life Sciences (NASDAQ:KZR) had its "market perform" rating reaffirmed by analysts at William Blair.